Weige Wang

机构：Apocare Pharma (Germany)

发表论文 50 篇 · 总被引 787 次 · h-index 17

代表论文

• XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB (2018 · Molecular Cancer Therapeutics · 被引 47)
• Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B‐cell lymphoma (2018 · The Journal of Pathology · 被引 26)
• Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues (2020 · Frontiers in Oncology · 被引 22)
• GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma (2022 · Cancer Biology & Therapy · 被引 20)
• Integrative analysis of PD ‐L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B‐cell lymphoma (2018 · Histopathology · 被引 20)
• Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label study (2023 · American Journal of Hematology · 被引 18)